Status:
UNKNOWN
MR Assessment of Hepatic Hydatid Disease
Lead Sponsor:
University College, London
Conditions:
Cystic Echincoccosis
Hydatid Disease
Eligibility:
All Genders
16+ years
Brief Summary
Hydatid disease is a major healthcare problem worldwide caused by infection that commonly affects the liver. Treatments for hydatid disease depend on how advanced the disease is and if the infection i...
Detailed Description
Cystic echincoccosis (CE), caused by infection with the dog tapeworm, is a major worldwide healthcare problem with increasing prevalence in the developed world. Approximately 75% of CE involves the li...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Control group:
- All patients must have cystic lesions which must exceed 30 mm in diameter.
- All patients must be fasted and avoid caffeinated fluids for at least 4 hours prior to the scan.
- All patients must be aged 16 or over and able to provide informed consent.
- Inclusion Criteria for the CE group:
- All patients must have hepatic CE, as confirmed by positive serology, with lesions identified on teh standard of care MRI/CT scan, one or more of which must exceed 20 mm in diameter.
- All patients must be fasted and avoid caffeinated fluids for at least 4 hours prior to the scan.
- All patients must be aged 16 or over and able to provide informed consent.
- Exclusion Criteria:
- Pregnancy
- Any contraindication to MRI (pacemakers, metallic implants, claustrophobia ect.)
- Inability to give consent
Exclusion
Key Trial Info
Start Date :
August 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03289884
Start Date
August 14 2017
End Date
March 1 2020
Last Update
May 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University College London Hospital
London, United Kingdom, NW1 2PG